Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 1 | Unknown | PO / MO |
The patient took the first dose of Vivotif with food and started eating lunch; Case reference number US-BN-2025-001534 is a spontaneous case initially received from a consumer via Communication (reference number: USBAV25-2270) on 11-Sep-2025 and concerns a 66-years-old female patient. The patient's medical history and concomitant medication details were not provided. On 10-Sep-2025, the patient took the first dose of Vivotif vaccine (batch number: unknown), at unknown dose, orally for indication of typhoid immunization. The patient took the first dose and started eating lunch (explicitly coded as 'product administration error'). At the time of the initial report, it was unknown if the patient experienced any of adverse events due to Vivotif. Additional information received from health care professional via Communications (reference number: USBAV25-2274) on 11-Sep-2025. Nwe information included: new reporter added.; Reporter's Comments: This case concerns a 66-years-old female patient. As reported the patient took the first dose of Vivotif vaccine and started eating lunch, for an indication of typhoid immunization, which is considered as 'product administration error'. Product administration error is considered as listed per company convention. At the time of the initial report, it was unknown if the patient experienced any of adverse events due to Vivotif. The patient's relevant medical history and concomitant medication details were not provided. Product administration error is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: This case concerns a 66-years-old female patient. As reported the patient took the first dose of Vivotif vaccine and started eating lunch, for an indication of typhoid immunization, which is considered as 'product administration error'. Product administration error is considered as listed per company convention. At the time of the initial report, it was unknown if the patient experienced any of adverse events due to Vivotif. The patient's relevant medical history and concomitant medication details were not provided. Product administration error is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None.